Melanotan II (MT-2) is a cyclic heptapeptide analogue of α-MSH developed at the University of Arizona as part of a melanocortin agonist programme. MT-2 exerts effects through non-selective agonism of the MC1R–MC5R receptor family, producing broad effects across pigmentation, sexual function, appetite, and energy regulation. The melanocortin pathway has since yielded three FDA-approved drugs: Vyleesi (PT-141), Scenesse (afamelanotide), and Imcivree.
- Melanogenesis and pigmentation — MC1R agonism activates eumelanin production for UV-protective pigmentation research.
- Sexual function research — pro-erectile effects discovered in early trials led directly to the FDA-approved drug bremelanotide (Vyleesi).
- Appetite and energy balance — MC4R agonism reduces food intake and body weight in animal models.
- Long-lasting pigmentation — MT-2-induced melanin deposition persists 4–6 weeks without maintenance dosing.
⚠️ For research use only. Not for human or animal consumption. Store at −20°C. Reconstitute with Bacteriostatic Water.



Reviews
There are no reviews yet.